Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 91 articles: HTML format

Single Articles

September 2025
1. JIANG C, He X, Chen X, Huang J, et al
   Lactate accumulation drives hepatocellular carcinoma metastasis through facilitating tumor-derived exosome biogenesis by Rab7A lactylation.
   Cancer Lett. 2025;627:217636.
   PubMed     Abstract available
   
   
   August 2025
2. YANG Y, Li Z, Yu X, Zheng Y, et al
   WDR11-DT enhances radiosensitivity via promoting PARP1 degradation and homologous recombination deficiency.
   Cancer Lett. 2025;625:217757.
   PubMed     Abstract available
   
   
   July 2025
3. LUCA AC, Kurnaeva M, John DK, Machtinger M, et al
   Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma.
   Cancer Lett. 2025;623:217733.
   PubMed     Abstract available
   
   
   
4. JIANG M, Zhang K, Wei G, Qi F, et al
   HDAC4 super-enhancer drives CEBPB-mediated TWIST2 transcription to promote chemoresistance in LUAD.
   Cancer Lett. 2025;623:217716.
   PubMed     Abstract available
   
   
   May 2025
5. WADE WEI TY, Hsia JY, Yang TY, Huang YX, et al
   Mechanistic Insights into CLNS1A-Mediated Chemoresistance and Tumor Progression in Non-small Cell Lung Cancer.
   Cancer Lett. 2025 May 7:217783. doi: 10.1016/j.canlet.2025.217783.
   PubMed     Abstract available
   
   
   April 2025
6. JIANG J, Chen H, Zhao C, Li T, et al
   PRTN3 promotes IL33/Treg-mediated tumor immunosuppression by enhancing the M2 polarization of tumor-associated macrophages in lung adenocarcinoma.
   Cancer Lett. 2025;616:217584.
   PubMed     Abstract available
   
   
   
7. LIN H, Hua J, Gong Z, Chen M, et al
   Multimodal radiopathological integration for prognosis and prediction of adjuvant chemotherapy benefit in resectable lung adenocarcinoma: A multicentre study.
   Cancer Lett. 2025;616:217557.
   PubMed     Abstract available
   
   
   
8. MO Y, Qin Y, Li P, Wu M, et al
   Thyroxine alleviates interstitial lung disease induced by combined radiotherapy and immunotherapy.
   Cancer Lett. 2025;615:217504.
   PubMed     Abstract available
   
   
   
9. XIAO X, Huang L, Li M, Zhang Q, et al
   Intersection between lung cancer and neuroscience: opportunities and challenges.
   Cancer Lett. 2025 Apr 5:217701. doi: 10.1016/j.canlet.2025.217701.
   PubMed     Abstract available
   
   
   March 2025
10. PENG X, Yang R, Wang C, Peng W, et al
    The YTHDF3-DT/miR-301a-3p /INHBA axis attenuates autophagy-dependent ferroptosis in lung adenocarcinoma.
    Cancer Lett. 2025;613:217503.
    PubMed     Abstract available
    
    
    
11. LI J, Xu S, Zhan Y, Lv X, et al
    CircRUNX1 enhances the Warburg effect and immune evasion in non-small cell lung cancer through the miR-145/HK2 pathway.
    Cancer Lett. 2025 Mar 14:217639. doi: 10.1016/j.canlet.2025.217639.
    PubMed     Abstract available
    
    
    
12. ZHAO L, Ren Y, Gong C, Xiong S, et al
    RMethyMD: An integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis.
    Cancer Lett. 2025;612:217462.
    PubMed     Abstract available
    
    
    
13. TANG X, Hu J, Guo R, Wang Y, et al
    RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs.
    Cancer Lett. 2025;612:217455.
    PubMed     Abstract available
    
    
    February 2025
14. FU R, Zhang C, Song MM, Gao X, et al
    A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment.
    Cancer Lett. 2025;616:217595.
    PubMed     Abstract available
    
    
    January 2025
15. HUANG M, Sun J, Jiang Q, Zhao X, et al
    CircKIAA0182-YBX1 Axis: A Key Driver of Lung Cancer Progression and Chemoresistance.
    Cancer Lett. 2025;612:217494.
    PubMed     Abstract available
    
    
    December 2024
16. YU JJ, Zhou DD, Cui B, Zhang C, et al
    Corrigendum to <[ Cancer Letters 474 (2020) 23-35]>.
    Cancer Lett. 2024 Dec 30:217434. doi: 10.1016/j.canlet.2024.217434.
    PubMed    
    
    
    
17. DONG XD, Zhang M, Teng QX, Lei ZN, et al
    Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies.
    Cancer Lett. 2024;607:217309.
    PubMed     Abstract available
    
    
    
18. HUANG S, Chung JY, Li C, Wu Y, et al
    Corrigendum to "Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma" [Cancer Lett. 604 (2024) 217272].
    Cancer Lett. 2024 Dec 27:217425. doi: 10.1016/j.canlet.2024.217425.
    PubMed    
    
    
    
19. YAMAMOTO G, Tanaka K, Kamata R, Saito H, et al
    WEE1 Confers Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer.
    Cancer Lett. 2024 Dec 24:217414. doi: 10.1016/j.canlet.2024.217414.
    PubMed     Abstract available
    
    
    
20. SUAY G, Garcia-Canaveras JC, Aparisi F, Garcia J, et al
    Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.
    Cancer Lett. 2024;606:217317.
    PubMed     Abstract available
    
    
    
21. NERLAKANTI N, McGuire JJ, Bishop RT, Nasr MM, et al
    Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis.
    Cancer Lett. 2024;606:217302.
    PubMed     Abstract available
    
    
    November 2024
22. LI J, Wang X, Cao G, Wu Y, et al
    CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and humanized murine models.
    Cancer Lett. 2024;605:217305.
    PubMed     Abstract available
    
    
    
23. ZHAO Y, Zhang D, Meng B, Zhang Y, et al
    Integrated proteomic and glycoproteomic analysis reveals heterogeneity and molecular signatures of brain metastases from lung adenocarcinomas.
    Cancer Lett. 2024;605:217262.
    PubMed     Abstract available
    
    
    
24. GE H, Malsiu F, Gao Y, Losmanova T, et al
    Inhibition of LDHB suppresses the metastatic potential of lung cancer by reducing mitochondrial GSH catabolism.
    Cancer Lett. 2024 Nov 28:217353. doi: 10.1016/j.canlet.2024.217353.
    PubMed     Abstract available
    
    
    
25. ZHANG J, Wu Q, Zhu L, Xie S, et al
    Corrigendum to "SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer" [Cancer Lett. 524 (2022) 268-283].
    Cancer Lett. 2024 Nov 23:217337. doi: 10.1016/j.canlet.2024.217337.
    PubMed    
    
    
    October 2024
26. PLAUGHER DR, Childress AR, Gosser CM, Esoe DP, et al
    Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer.
    Cancer Lett. 2024 Oct 4:217281. doi: 10.1016/j.canlet.2024.217281.
    PubMed     Abstract available
    
    
    
27. WU J, Chen Y, Zou H, Xu K, et al
    6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells.
    Cancer Lett. 2024;601:217177.
    PubMed     Abstract available
    
    
    September 2024
28. HUANG L, Liu X, Chen Q, Yang J, et al
    TGF-beta-induced lncRNA TBUR1 promotes EMT and metastasis in lung adenocarcinoma via hnRNPC-mediated GRB2 mRNA stabilization.
    Cancer Lett. 2024;600:217153.
    PubMed     Abstract available
    
    
    
29. WU J, Zhao Q, Chen S, Xu H, et al
    NSUN4-mediated m5C modification of circERI3 promotes lung cancer development by altering mitochondrial energy metabolism.
    Cancer Lett. 2024 Sep 25:217266. doi: 10.1016/j.canlet.2024.217266.
    PubMed     Abstract available
    
    
    
30. HUANG S, Yat-Fai Chung J, Li C, Wu Y, et al
    Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma.
    Cancer Lett. 2024 Sep 24:217272. doi: 10.1016/j.canlet.2024.217272.
    PubMed     Abstract available
    
    
    
31. GARGALIONIS AN, Papavassiliou KA, Basdra EK, Papavassiliou AG, et al
    Exploiting tumor mechanomedicine for lung cancer treatment.
    Cancer Lett. 2024;604:217229.
    PubMed    
    
    
    
32. GANG X, Yan J, Li X, Shi S, et al
    Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions.
    Cancer Lett. 2024 Sep 9:217241. doi: 10.1016/j.canlet.2024.217241.
    PubMed     Abstract available
    
    
    
33. LA VECCHIA S, Fontana S, Salaroglio IC, Anobile DP, et al
    Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy.
    Cancer Lett. 2024;604:217221.
    PubMed     Abstract available
    
    
    
34. WEI X, Uchibori K, Kondo N, Utsumi T, et al
    MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
    Cancer Lett. 2024 Sep 5:217220. doi: 10.1016/j.canlet.2024.217220.
    PubMed     Abstract available
    
    
    
35. SUN SY
    Is tumor microenvironment important for targeted therapy in lung cancer?
    Cancer Lett. 2024 Sep 3:217203. doi: 10.1016/j.canlet.2024.217203.
    PubMed    
    
    
    
36. XUE R, Li X, Yang L, Yang M, et al
    Evaluation and integration of cell-free DNA signatures for detection of lung cancer.
    Cancer Lett. 2024 Sep 2:217216. doi: 10.1016/j.canlet.2024.217216.
    PubMed     Abstract available
    
    
    August 2024
37. LI J, Bai M, Jia W, Zhai X, et al
    Irradiated tumor cell-released microparticles enhance the therapeutic efficacy of PD-1 inhibitors by promoting M1-TAMs polarization in NSCLC brain metastases.
    Cancer Lett. 2024;598:217133.
    PubMed     Abstract available
    
    
    
38. LU Y, Sun Y, Zhang J, Kong M, et al
    The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.
    Cancer Lett. 2024;596:217020.
    PubMed     Abstract available
    
    
    
39. FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al
    Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
    Cancer Lett. 2024;596:217001.
    PubMed     Abstract available
    
    
    
40. KIM YJ, Lee M, Kim EH, Lee S, et al
    Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Cancer Lett. 2024;596:216998.
    PubMed     Abstract available
    
    
    
41. CHOW Z, Johnson J, Chauhan A, Jeong JC, et al
    Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
    Cancer Lett. 2024;596:216993.
    PubMed     Abstract available
    
    
    July 2024
42. HUANG L, Wang J, Wang X, Zheng S, et al
    Sulforaphane suppresses bladder cancer metastasis via blocking actin nucleation-mediated pseudopodia formation.
    Cancer Lett. 2024 Jul 29:217145. doi: 10.1016/j.canlet.2024.217145.
    PubMed     Abstract available
    
    
    
43. LIU M, Gu L, Zhang Y, Li Y, et al
    LKB1 inhibits telomerase activity resulting in cellular senescence through histone lactylation in lung adenocarcinoma.
    Cancer Lett. 2024;595:217025.
    PubMed     Abstract available
    
    
    
44. NAKAMURA R, Yamada T, Tokuda S, Morimoto K, et al
    Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
    Cancer Lett. 2024;598:217124.
    PubMed     Abstract available
    
    
    
45. SINGH D, Qiu Z, Jonathan SM, Fa P, et al
    PP2A B55alpha Inhibits Epithelial-Mesenchymal Transition Via Regulation of Slug Expression in Non-Small Cell Lung Cancer.
    Cancer Lett. 2024 Jul 8:217110. doi: 10.1016/j.canlet.2024.217110.
    PubMed     Abstract available
    
    
    
46. LI X, Shang S, Wu M, Song Q, et al
    Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis.
    Cancer Lett. 2024;598:217096.
    PubMed     Abstract available
    
    
    
47. SHU M, Huang L, Chen Y, Wang Y, et al
    Identification of a DNA-methylome-based signature for prognosis prediction in driver gene-negative lung adenocarcinoma.
    Cancer Lett. 2024;593:216835.
    PubMed     Abstract available
    
    
    June 2024
48. GUGNONI M, Lorenzini E, Torricelli F, Donati B, et al
    Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC translation in malignant pleural mesothelioma.
    Cancer Lett. 2024;592:216950.
    PubMed     Abstract available
    
    
    
49. HE Q, Qu M, Xu C, Wu L, et al
    Smoking-induced CCNA2 expression promotes lung adenocarcinoma tumorigenesis by boosting AT2/AT2-like cell differentiation.
    Cancer Lett. 2024;592:216922.
    PubMed     Abstract available
    
    
    
50. XU Z, Shi Y, Zhu L, Luo J, et al
    Novel SERCA2 inhibitor Diphyllin displays anti-tumor effect in non-small cell lung cancer by promoting endoplasmic reticulum stress and mitochondrial dysfunction.
    Cancer Lett. 2024 Jun 21:217075. doi: 10.1016/j.canlet.2024.217075.
    PubMed     Abstract available
    
    
    
51. GUO W, Qiao T, Li H, Zhao Y, et al
    Peripheral CD8(+)PD-1(+) T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer.
    Cancer Lett. 2024;597:217073.
    PubMed     Abstract available
    
    
    
52. LIU X, Zheng W, Zhang L, Cao Z, et al
    Corrigendum to "Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer cell proliferation" [Cancer Lett. 586 (2024) 216707/CAN_216707].
    Cancer Lett. 2024 Jun 5:217003. doi: 10.1016/j.canlet.2024.217003.
    PubMed    
    
    
    
53. ZHENG L, Shen J, Chen Y, Lin J, et al
    FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2.
    Cancer Lett. 2024;591:216848.
    PubMed     Abstract available
    
    
    May 2024
54. ZHANG L, Xu Y, Cheng Z, Zhao J, et al
    The EGR1/miR-139/NRF2 axis orchestrates radiosensitivity of non-small-cell lung cancer via ferroptosis.
    Cancer Lett. 2024;595:217000.
    PubMed     Abstract available
    
    
    
55. BOSSE Y, Dasgupta A, Abadier M, Guthrie V, et al
    Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
    Cancer Lett. 2024;594:216984.
    PubMed     Abstract available
    
    
    
56. JIANG Y, Li S, Ramesh R
    Identification of SMARCAL1 as a molecular target for small cell lung cancer treatment.
    Cancer Lett. 2024 May 10:216932. doi: 10.1016/j.canlet.2024.216932.
    PubMed    
    
    
    
57. CHEN X, Yuan M, Zhong T, Wang M, et al
    LILRB2 Inhibition Enhances Radiation Sensitivity in Non-Small Cell Lung Cancer by Attenuating Radiation-Induced Senescence.
    Cancer Lett. 2024 May 3:216930. doi: 10.1016/j.canlet.2024.216930.
    PubMed     Abstract available
    
    
    
58. WANG PS, Liu Z, Sweef O, Saeed AF, et al
    Hexavalent chromium exposure activates the non-canonical nuclear factor kappa B pathway to promote immune checkpoint protein programmed death-ligand 1 expression and lung carcinogenesis.
    Cancer Lett. 2024;589:216827.
    PubMed     Abstract available
    
    
    
59. YU T, Liu Z, Tao Q, Xu X, et al
    Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming.
    Cancer Lett. 2024;589:216824.
    PubMed     Abstract available
    
    
    
60. LUO S, Luo Y, Wang Z, Yin H, et al
    Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.
    Cancer Lett. 2024;589:216811.
    PubMed     Abstract available
    
    
    April 2024
61. SUN BB, Wang GZ, Han SC, Yang FY, et al
    Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer.
    Cancer Lett. 2024 Apr 30:216929. doi: 10.1016/j.canlet.2024.216929.
    PubMed     Abstract available
    
    
    
62. YOKOTA E, Iwai M, Yukawa T, Naomoto Y, et al
    Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
    Cancer Lett. 2024;588:216816.
    PubMed     Abstract available
    
    
    
63. MOON JW, Hong BJ, Kim SK, Park MS, et al
    Systematic identification of a synthetic lethal interaction in brain-metastatic lung adenocarcinoma.
    Cancer Lett. 2024;588:216781.
    PubMed     Abstract available
    
    
    
64. LUO J, Cheng K, Ji X, Gao C, et al
    Anlotinib enhanced CD8(+) T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer.
    Cancer Lett. 2024;591:216892.
    PubMed     Abstract available
    
    
    
65. MORIMOTO K, Yamada T, Hirai S, Katayama Y, et al
    AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
    Cancer Lett. 2024;587:216692.
    PubMed     Abstract available
    
    
    
66. GAO GB, Chen L, Pan JF, Lei T, et al
    LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer.
    Cancer Lett. 2024 Apr 2:216826. doi: 10.1016/j.canlet.2024.216826.
    PubMed     Abstract available
    
    
    
67. HAO Z, Xin Z, Chen Y, Shao Z, et al
    JAML promotes the antitumor role of tumor-resident CD8(+) T cells by facilitating their innate-like function in human lung cancer.
    Cancer Lett. 2024 Apr 1:216839. doi: 10.1016/j.canlet.2024.216839.
    PubMed     Abstract available
    
    
    March 2024
68. ZHANG E, Sun Q, Zhang C, Ma H, et al
    Comprehensive functional interrogation of susceptibility loci in GWASs identified KIAA0391 as a novel oncogenic driver via regulating pyroptosis in NSCLC.
    Cancer Lett. 2024;585:216646.
    PubMed     Abstract available
    
    
    
69. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    PubMed     Abstract available
    
    
    
70. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
    Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Cancer Lett. 2024;584:216608.
    PubMed     Abstract available
    
    
    February 2024
71. HAN R, Lin C, Lu C, Wang Y, et al
    Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
    Cancer Lett. 2024;588:216762.
    PubMed     Abstract available
    
    
    
72. LIU X, Zheng W, Zhang L, Cao Z, et al
    Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer cell proliferation.
    Cancer Lett. 2024 Feb 6:216707. doi: 10.1016/j.canlet.2024.216707.
    PubMed     Abstract available
    
    
    
73. LU X, Yu R, Li Z, Yang M, et al
    JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
    Cancer Lett. 2024;582:216517.
    PubMed     Abstract available
    
    
    
74. LIN S, He C, Song L, Sun L, et al
    Exosomal lncCRLA is predictive for the evolvement and development of lung adenocarcinoma.
    Cancer Lett. 2024;582:216588.
    PubMed     Abstract available
    
    
    
75. BISWAS U, Roy R, Ghosh S, Chakrabarti G, et al
    The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics.
    Cancer Lett. 2024 Feb 1:216662. doi: 10.1016/j.canlet.2024.216662.
    PubMed     Abstract available
    
    
    January 2024
76. SUN J, Dong M, Xiang X, Zhang S, et al
    Notch signaling and targeted therapy in non-small cell lung cancer.
    Cancer Lett. 2024 Jan 30:216647. doi: 10.1016/j.canlet.2024.216647.
    PubMed     Abstract available
    
    
    
77. SUI Q, Hu Z, Liang J, Lu T, et al
    Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma.
    Cancer Lett. 2024;581:216497.
    PubMed     Abstract available
    
    
    
78. ZHANG H, Li S, Zhou R, Dong T, et al
    SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.
    Cancer Lett. 2024;585:216667.
    PubMed     Abstract available
    
    
    
79. ZHOU X, Jia Y, Mao C, Liu S, et al
    Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy.
    Cancer Lett. 2024;580:216481.
    PubMed     Abstract available
    
    
    December 2023
80. YANG Y, Wang J, Wang J, Zhao X, et al
    Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.
    Cancer Lett. 2023 Dec 13:216569. doi: 10.1016/j.canlet.2023.216569.
    PubMed     Abstract available
    
    
    
81. MENG Y, Lin W, Wang N, Wei X, et al
    USP7-mediated ERbeta stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma.
    Cancer Lett. 2023 Dec 12:216587. doi: 10.1016/j.canlet.2023.216587.
    PubMed     Abstract available
    
    
    
82. XIE Y, Zhang L, Wang L, Chen B, et al
    EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer.
    Cancer Lett. 2023;582:216567.
    PubMed     Abstract available
    
    
    
83. YUAN Y, Li Y, Wu X, Bo J, et al
    POH1 induces Smad3 deubiquitination and promotes lung cancer metastasis.
    Cancer Lett. 2023 Dec 5:216526. doi: 10.1016/j.canlet.2023.216526.
    PubMed     Abstract available
    
    
    
84. KONG R, Wei W, Man Q, Chen L, et al
    Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma.
    Cancer Lett. 2023;578:216442.
    PubMed     Abstract available
    
    
    November 2023
85. ZHOU Y, Guo Y, Ran M, Shan W, et al
    Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.
    Cancer Lett. 2023;577:216425.
    PubMed     Abstract available
    
    
    
86. NAMKAEW J, Zhang J, Yamakawa N, Hamada Y, et al
    Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer.
    Cancer Lett. 2023 Nov 28:216509. doi: 10.1016/j.canlet.2023.216509.
    PubMed     Abstract available
    
    
    
87. CAI S, Zhang B, Huang C, Deng Y, et al
    CTRP6 protects against ferroptosis to drive lung cancer progression and metastasis by destabilizing SOCS2 and augmenting the xCT/GPX4 pathway.
    Cancer Lett. 2023;579:216465.
    PubMed     Abstract available
    
    
    
88. LI B, Chen Q, Feng Y, Wei T, et al
    Glucose restriction induces AMPK-SIRT1-mediated circadian clock gene Per expression and delays NSCLC progression.
    Cancer Lett. 2023;576:216424.
    PubMed     Abstract available
    
    
    October 2023
89. HUA WJ, Yeh H, Lin ZH, Tseng AJ, et al
    Ganoderma microsporum immunomodulatory protein as an extracellular epidermal growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung cancer cells.
    Cancer Lett. 2023;578:216458.
    PubMed     Abstract available
    
    
    
90. ZHANG Q, Zheng L, Bai Y, Su C, et al
    ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21(HRAS) splicing and stabilizing DDX3X to activate the cRaf-MEK-ERK cascade.
    Cancer Lett. 2023 Oct 9:216426. doi: 10.1016/j.canlet.2023.216426.
    PubMed     Abstract available
    
    
    September 2023
91. LIU X, Li R, Chen X, Yao J, et al
    SYT7 is a key player in increasing exosome secretion and promoting angiogenesis in non-small-cell lung cancer.
    Cancer Lett. 2023 Sep 27:216400. doi: 10.1016/j.canlet.2023.216400.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.